JC Neel is a Venture Partner at IKJ Capital who trained as a cell and molecular biologist, with years of academic and industry research spanning microRNA biology, TGFβ signaling, vascular biology, and reproductive biology, and he focuses closely on organoids and advanced cell models, advising biotech startups like Opal Therapeutics and APstem Therapeutics while also serving as Chief Scientific Officer at Incite. His path has taken him from Neuralink to family-office biotech investing, and at Incite he has spoken about reducing bias in decision-making by pushing for unbiased ranking and third-party validation to move faster on rare disease research.